Guidance On Nucleic Acid-Based IVDs Recommends Analytical, Clinical Studies
This article was originally published in The Gray Sheet
Executive Summary
An FDA final guidance released Aug. 27 on highly multiplexed microbiological in vitro nucleic-acid based diagnostics recommends studies on both the analytical and clinical performance of the devices.
You may also be interested in...
FDA Downclassifies Multiplex Nucleic Acid Assays
FDA has decided to relax its classification of multiplex nucleic acid assays to detect microorganisms and resistance markers in the blood but with special controls to mitigate concerns with potential to misinterpret test results.
Regulatory News In Brief
FDA issues final guidance on IDE and PMA requirements for artificial pancreas devices. CDRH plans Office of Compliance reorganization. More regulatory news.
Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.